Journal
ACS APPLIED BIO MATERIALS
Volume 6, Issue 7, Pages 2644-2650Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsabm.3c00260
Keywords
NIR-II; MRI; Herceptin; breast cancer; bioimaging
Ask authors/readers for more resources
We developed a small MRI/NIR-II probe for HER2 breast cancer cells. The probe contains PLGA-b-PEG micelles encapsulated with NIR-II and Gd-DOTA conjugated at the border of PLGA/PEG. Herceptin is then conjugated to carboxyl residues of PLGA-b-PEG chains. Through binding assays, we found that the optimal surface ratio of -COOH is 5% for stable probe properties and high antigen-capturing activity.
We developed a small MRI/NIR-II probeto target HER2(tetanucleotide)breast cancer cells. The probe is composed of PLGA-b-PEG micelles encapsulated NIR-II, and Gd-DOTA is conjugated at theborder of PLGA/PEG. Herceptin was then conjugated to carboxyl residuesof PLGA-b-PEG chains. We examined the influence ofcarboxyl group ratios on the probe property stability and Herceptinconcentration and the binding affinity to HER2(+) cells correspondingto the -COOH ratios. The binding assays demonstrated that theoptimal surface ratio of -COOH is 5%, which is less affectedby fluorescence reduction and which exhibited the highest antigen-capturingactivity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available